CLAIMS

What is claimed is:

1. A method of treating neurodegenerative inflammation in a human in need thereof, comprising administering to the cerebrospinal fluid (CSF) of said human an effective TNF-inhibiting amount of an anti-TNF antibody or TNF binding fragment thereof sufficient to treat the neurodegenerative inflammation.

2. A method of treating neurodegenerative inflammation in a human in need thereof, comprising administering to the cerebrospinal fluid (CSF) of said human an effective TNF-inhibiting amount of an anti-TNF antibody or TNF binding fragment thereof sufficient to treat the neurodegenerative inflammation, wherein said anti-TNF antibody or fragment is a chimeric TNF antibody.

3. A method of treating neurodegenerative inflammation in a human in need thereof, comprising administering to the cerebrospinal fluid (CSF) of said human an effective TNF-inhibiting amount of an anti-TNF antibody or TNF binding fragment thereof sufficient to treat the neurodegenerative inflammation, wherein said anti-TNF antibody or fragment competitively inhibits the binding of TNF to the TNF antibody cA2 .

4. The method of Claim 3, wherein the chimeric TNF antibody comprises non-human variable region.

5. The method of Claim 1, wherein said administration comprises a single or divided 0.1 - 100 mg/kg dose of said anti-TNF antibody or fragment thereof.

6. The method of Claim 2, wherein said administration comprises a single or divided 0.1 - 100 mg/kg dose of said anti-TNF antibody or fragment thereof.

7. The method of Claim 3, wherein said administration comprises a single or divided 0.1 - 100 mg/kg dose of said anti-TNF antibody or fragment thereof.

8. The method of Claim 1 further comprising administering to the human an effective amount of a therapeutic agent selected from the group consisting of: disease-modifying anti-rheumatic drugs, anti-inflammatory agents, anti-neoplastic agents, radionuclides, radiotherapeutics, immunosuppressives, cytotoxic drugs, monoclonal antibodies, murine antibodies, chimeric antibodies, antibody fragments, antibody regions, lymphokines, cytokines, hemopoietic growth factors and immunoglobulins.

9. The method of Claim 2 further comprising administering to the human an effective amount of a therapeutic agent selected from the group consisting of: disease-modifying anti-rheumatic drugs, anti-inflammatory agents, anti-neoplastic agents, radionuclides, radiotherapeutics, immunosuppressives, cytotoxic drugs, monoclonal antibodies, murine antibodies, chimeric antibodies, antibody fragments, antibody regions, lymphokines, cytokines, hemopoietic growth factors and immunoglobulins.

10. The method of Claim 3 further comprising administering to the human an effective amount of a therapeutic agent selected from the group consisting of: disease-modifying anti-rheumatic drugs, anti-inflammatory agents, anti-neoplastic agents, radionuclides, radiotherapeutics, immunosuppressives, cytotoxic drugs,

monoclonal antibodies, murine antibodies, chimeric antibodies, antibody fragments, antibody regions, lymphokines, cytokines, hemopoietic growth factors and immunoglobulins.

11. The method of Claim 8, wherein the therapeutic agent is a disease-modifying anti-rheumatic drug.

12. The method of Claim 11, wherein the disease-modifying anti-rheumatic drug is selected from the group consisting of: auranofin, azathioprine, chloroquine, D-penicillamine, gold sodium thiomalate hydroxychloroquine, Myocrisin and sulfasalzine methotrexate.

13. The method of Claim 8, wherein the therapeutic agent is an anti-inflammatory agent.

14. The method of Claim 13, wherein the anti-inflammatory agent is selected from the group consisting of: pentasa, mesalazine, asacol, codeine phosphate, benorylate, fenbufen, naprosyn, diclofenac, etodolac and indomethacin, aspirin and ibuprofen.

15. The method of Claim 8, wherein the therapeutic agent is a pain control agent.

16. The method of Claim 15, wherein the pain control agent is selected from the group consisting of: paracetamol and dextropropoxyphene.

17. The method of Claim 1 further comprising administering to the human an effective amount of at least one therapeutic agent selected from the group consisting of: at least one antibiotic and at least one steroid.

18. The method of Claim 1, wherein the anti-TNF chimeric antibody is of immunoglobulin class IgG1, IgG2, IgG3, IgG4 or IgM.

19. The method of Claim 1, wherein the anti-TNF chimeric antibody is a fragment selected from the group consisting of Fab, Fab', $F(ab')_2$ and Fv.